Valuation: Delcath Systems, Inc.

Market Cap 60Cr 52Cr 49Cr 44Cr 84Cr 5.76TCr 85Cr 572.84Cr 223.97Cr 2.88TCr 226.16Cr 221.25Cr 9.59TCr P/E 2026 *
-116x
P/E 2027 * -217x
Enterprise Value 60Cr 52Cr 49Cr 44Cr 84Cr 5.76TCr 85Cr 572.84Cr 223.97Cr 2.88TCr 226.16Cr 221.25Cr 9.59TCr EV / Sales 2026 *
5.67x
EV / Sales 2027 * 4.56x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-0.53%+9.30%-26.95% 2TCr
+0.92%+2.12%+6.79%+1.82% 1.74TCr
-0.25%+6.04%-57.36%-42.87% 618.39Cr
0.00%-0.51% - - 428.18Cr
0.00%+2.61%+40.27%+37.61% 205.59Cr
+0.17%+1.70%-2.45%-5.24% 195.81Cr
-2.19%+5.88%-46.75%-55.78% 124.62Cr
+11.89%+8.66%+75.42%+195.71% 88Cr
-3.34%+10.95%+60.12%+437.34% 60Cr
Average +0.90%+2.94%+10.67%+67.71% 607.38Cr
Weighted average by Cap. +0.48%+1.76%+1.44%-6.74%

Financials

2026 *2027 *
Net sales 11Cr 9.17Cr 8.62Cr 7.84Cr 15Cr 1.02TCr 15Cr 101Cr 39Cr 508.58Cr 40Cr 39Cr 1.69TCr 13Cr 11Cr 11Cr 9.74Cr 18Cr 1.26TCr 19Cr 125.51Cr 49Cr 631.99Cr 50Cr 48Cr 2.1TCr
Net income -57.21L -49.41L -46.43L -42.23L -79.39L -55Cr -80.7L -5.44Cr -2.13Cr -27Cr -2.15Cr -2.1Cr -91Cr -33.88L -29.26L -27.5L -25.01L -47.02L -32Cr -47.79L -3.22Cr -1.26Cr -16Cr -1.27Cr -1.24Cr -54Cr
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-